DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/ht3chw/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Rheumatoid Arthritis Therapeutics Market" report to their offering.
This market insight discusses the rheumatoid arthritis pharmaceutical drugs currently in the global market as well as those in the development stage. It offers a competitive analysis of the drugs and a forecast of their impact on the market.
Drugs in the development stage are segmented by clinical trial phase as well as by drug class. The study covers profiles of late-stage investigational products close to being launched, patent expiration timelines, products in clinical development, launched product profiles, and new product launch timelines.
- The number of people globally with RA is million in 2014. The chronic disease is more prevalent in elderly patients.
- The tumor necrosis factor (TNF) inhibitors Enbrel, Humira, and Remicade dominate the market as first-line standards of care.
- The TNF inhibitors are well entrenched and are expected to continue to dominate the market during 2015 and 2016, until the launch of new drug classes for the treatment of RA.
- New biologics arriving in the market will impact TNF inhibitors' share. However, novel orals and biologics are generally reserved for anti-TNF refractory patients.
- High costs make biologics inaccessible to many patients, resulting in a need for less costly options without sacrificing safety or efficacy. Biosimilars, such as infliximab, which were launched in emerging markets, are expected to be the choice of many patients who are not able to purchase biologics.
- There are 11 marketed products globally, and 14 are in Phase III clinical trials. The research and development (R&D) trend is to develop TNF, interleukin, and Janus kinase (JAK) inhibitors, as well as Anti-Cluster of Differentiation (CD) products. R&D is focused on increasing efficacy and safety as well as lifestyle quality by changing the administration forms from subcutaneous to oral.
Three products are expected to be launched in the United States in 2016:
- Bariticinib, developed by Eli Lilly, is an oral medication which causes fewer side effects than Pfizer's tofacitinib, Xeljanz.
- BCD-020, developed by Biocad, is expected to make a major impact in the market for being the first anti-CD20 biosimilar approved for RA.
- SAR153191/REGN88, developed by Sanofi and Regeneron, is the first fully human monoclonal antibody anti-IL-6.
Key Topics Covered:
1. Executive Summary
2. Market Overview
3. External Challenges: Drivers and Restraints-Total Rheumatoid Arthritis Therapeutics Market
4. Competitive Analysis-Total Rheumatoid Arthritis Therapeutics Market
5. Profiles of Late-stage Investigational Products Close to be Launched
6. The Last Word
- Eli Lilly
For more information visit http://www.researchandmarkets.com/research/ht3chw/product_and